Toxicology and teratology of the active ingredients of professional therapy MuscleCare products during pregnancy and lactation: a systematic review

BMC Complementary and Alternative Medicine

Gideon Koren¹  Colleen Fox³  Abdulaziz MS Alsaad² 

[1]Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College street, Toronto M5S 3M2, ON, Canada

[2]Department of Pharmacology & Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

[3]Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics, Hospital for Sick Children and University of Toronto, 555 University Ave, Toronto M5G 1X8, ON, Canada

关键词: Safety;    Teratogenicity;    Lactation;    Pregnancy;    MuscleCare;   

Others  :  1136447
DOI  :  10.1186/s12906-015-0585-8

 received in 2014-09-19, accepted in 2015-02-24,  发布年份 2015

【 摘 要 】

Background

The rates of muscle aches, sprains, and inflammation are significantly increased during pregnancy. However, women are afraid to use systemic analgesics due to perceptions of fetal risks. Thus, topical products are important alternatives to consider for those women. Of interest, Professional Therapy MuscleCare (PTMC) has shown to be effective in alleviating the myofascial pain as reported in a randomized, placebo-controlled double-blinded comparative clinical study of five topical analgesics. However, to date, there is no complete review or long-term safety studies on the safety of these products during pregnancy and lactation. Thus, the aim of this article was to review toxicological, developmental, and reproductive effects associated with the use of PTMC products.

Methods

We performed a systematic review on safety of PTMC from all toxicological articles investigating the effects of PTMC’s ingredients. This search was conducted through medical and toxicological databases including, Web of Science, EMBASE, Medline, and Micromedix. Both reported and theoretical adverse effects were extensively reviewed.

Results

Of the 1500 publications reviewed, 100 papers were retrieved and included in the review. Although some ingredients in PTMC products might cause adverse reproductive effects at high systemic doses, these doses are hundreds to thousands fold greater than those systemically available from topical use at the recommended maximum dose (i.e. 10 g/day).

Conclusions

This study provides evidence that, when used as indicated, PTMC is apparently safe for pregnant women and their unborn babies as well as for breastfed infants.

【 授权许可】

   
2015 Alsaad et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Foti T, Davids JR, Bagley A: A biomechanical analysis of gait during pregnancy. J Bone Joint Surg Am 2000, 82(5):625-32.
• [2]Kalus SM, Kornman LH, Quinlivan JA: Managing back pain in pregnancy using a support garment: a randomised trial. BJOG 2008, 115(1):68-75.
• [3]Mogren I: Perceived health, sick leave, psychosocial situation, and sexual life in women with low-back pain and pelvic pain during pregnancy. Acta Obstet Gynecol Scand 2006, 85(6):647-56.
• [4]Skaggs CD, Prather H, Gross G, George JW, Thompson PA, Nelson DM: Back and pelvic pain in an underserved United States pregnant population: a preliminary descriptive survey. J Manipulative Physiol Ther 2007, 30(2):130-4.
• [5]Greenwood CJ, Stainton MC: Back pain/discomfort in pregnancy: invisible and forgotten. J Perinat Educ 2001, 10(1):1-12.
• [6]Avrahami D, Hammond A, Higgins C, Vernon H: A randomized, placebo-controlled double-blinded comparative clinical study of five over-the-counter non-pharmacological topical analgesics for myofascial pain: single session findings. Chiropr Man Therap 2012, 20:7.
• [7]Vermani E, Mittal R, Weeks A: Pelvic girdle pain and low back pain in pregnancy: a review. Pain Pract 2010, 10(1):60-71.
• [8]Vleeming A, Albert HB, Ostgaard HC, Sturesson B, Stuge B: European guidelines for the diagnosis and treatment of pelvic girdle pain. Eur Spine J 2008, 17(6):794-819.
• [9]MacLennan AH, Nicolson R, Green RC, Bath M: Serum relaxin and pelvic pain of pregnancy. Lancet 1986, 2(8501):243-5.
• [10]Cardwell MS: Stress: pregnancy considerations. Obstet Gynecol Surv 2013, 68(2):119-29.
• [11]Childs SJ: Dimethyl sulfone (DMSO2) in the treatment of interstitial cystitis. Urol Clin North Am 1994, 21(1):85-8.
• [12]Barrager E, Veltmann JR Jr, Schauss AG, Schiller RN: A multicentered, open-label trial on the safety and efficacy of methylsulfonylmethane in the treatment of seasonal allergic rhinitis. J Altern Complement Med 2002, 8(2):167-73.
• [13]Horvath K, Noker PE, Somfai-Relle S, Glavits R, Financsek I, Schauss AG: Toxicity of methylsulfonylmethane in rats. Food Chem Toxicol 2002, 40(10):1459-62.
• [14]Garrettson LK, Procknal JA, Levy G: Fetal acquisition and neonatal elimination of a large amount of salicylate. Study of a neonate whose mother regularly took therapeutic doses of aspirin during pregnancy. Clin Pharmacol Ther 1975, 17(1):98-103.
• [15]Magnuson BA, Appleton J, Ryan B, Matulka RA: Oral developmental toxicity study of methylsulfonylmethane in rats. Food Chem Toxicol 2007, 45(6):977-84.
• [16]Magnuson BA, Appleton J, Ames GB: Pharmacokinetics and distribution of [35S]methylsulfonylmethane following oral administration to rats. J Agric Food Chem 2007, 55(3):1033-8.
• [17]Manoguerra AS, Erdman AR, Wax PM, Nelson LS, Caravati EM, Cobaugh DJ, et al.: Camphor poisoning: an evidence-based practice guideline for out-of-hospital management. Clin Toxicol (Phila) 2006, 44(4):357-70.
• [18]Martin D, Valdez J, Boren J, Mayersohn M: Dermal absorption of camphor, menthol, and methyl salicylate in humans. J Clin Pharmacol 2004, 44(10):1151-7.
• [19]Love JN, Sammon M, Smereck J: Are one or two dangerous? Camphor exposure in toddlers. J Emerg Med 2004, 27(1):49-54.
• [20]Weiss J, Catalano P: Camphorated oil intoxication during pregnancy. Pediatrics 1973, 52(5):713-4.
• [21]Heinonen OP, Slone D, Shapiro S: Birth defects and drugs in pregnancy. Publishing Sciences Group Inc, Littleton, Mass; 1977.
• [22]Leuschner J: Reproductive toxicity studies of D-camphor in rats and rabbits. Drug Res 1997, 47(2):124-8.
• [23]NTP (National Toxicology Program). Developmental toxicity evaluation of d-camphor (CAS No. 464-49-3) administered by gavage to Sprague-Dawley (CD®) rats on gestational days 6 through 15. Abstract for TER91018. 1992. Final study report and appendix. http://ntp.niehs.nih.gov/testing/types/dev/abstracts/pages/ter91018/index.html. Accessed on 21 Sept 2014.
• [24]NTP (National Toxicology Program). Developmental toxicity evaluation of d-camphor (CAS No. 464-49-3) administered by gavage to New Zealand White (NZW) rabbits on gestational days 6 through 19. Abstract for TER91019. 1992. Final study report and appendix. http://ntp.niehs.nih.gov/testing/types/dev/abstracts/pages/ter91019/index.html. Accessed on 21 Sept 2014.
• [25]Blackmon WP, Curry HB: Camphor poisoning; report of case occurring during pregnancy. JFMA 1957, 43(10):999-1000.
• [26]Jacobziner H, Raybin HW: Camphor poisoning. Arch Pediatr Adolesc Med 1962, 79:28-30.
• [27]Riggs J, Hamilton R, Homel S, McCabe J: Camphorated oil intoxication in pregnancy; report of a case. Obstet Gynecol 1965, 25:255-8.
• [28]Czeizel AE, Toth M: Birth weight, gestational age and medications during pregnancy. Int J Gynaecol Obstet 1998, 60(3):245-9.
• [29]Patel T, Ishiuji Y, Yosipovitch G: Menthol: a refreshing look at this ancient compound. J Am Acad Dermatol 2007, 57(5):873-8.
• [30]Thorup I, Wurtzen G, Carstensen J, Olsen P: Short term toxicity study in rats dosed with pulegone and menthol. Toxicol Lett 1983, 19(3):207-10.
• [31]Food & Drug Research Labs Inc. Teratologic evaluation of FDA 71–57 (menthol natural Brazilian). 1973. http://www.inchem.org/documents/jecfa/jecmono/v042je04.htm. Accessed on 21 Sept 2014.
• [32]Cosmetic Ingredient Review Expert Panel. Safety assessment of Salicylic Acid, Butyloctyl Salicylate, Calcium Salicylate, C12-15 Alkyl Salicylate, Capryloyl Salicylic Acid, Hexyldodecyl Salicylate, Isocetyl Salicylate, Isodecyl Salicylate, Magnesium Salicylate, MEA-Salicylate, Ethylhexyl Salicylate, Potassium Salicylate, Methyl Salicylate, Myristyl Salicylate, Sodium Salicylate, TEA-Salicylate, and Tridecyl Salicylate. Int J Toxicol. 2003;22 Suppl 3:1–108.
• [33]Heng MC: Local necrosis and interstitial nephritis due to topical methyl salicylate and menthol. Cutis 1987, 39(5):442-4.
• [34]Davis JE: Are one or two dangerous? Methyl salicylate exposure in toddlers. J Emerg Med 2007, 32(1):63-9.
• [35]Mills PC, Cross SE: Regional differences in the in vitro penetration of methylsalicylate through equine skin. Vet J 2007, 173(1):57-61.
• [36]Warkany J, Takacs E: Experimental production of congenital malformations in rats by salicylate poisoning. Am J Pathol 1959, 35(2):315-31.
• [37]Overman DO, White JA: Comparative teratogenic effects of methyl salicylate applied orally or topically to hamsters. Teratology 1983, 28(3):421-6.
• [38]Briggs GG, Freeman RK, Yaffe SJMD: Drugs in pregnancy and lactation for PDA: a reference guide to fetal and neonatal risk. Lippincott Williams & Wilkins, Baltimore, MD; 2002.
• [39]Daston GP, Rehnberg BF, Carver B, Rogers EH, Kavlock RJ: Functional teratogens of the rat kidney. I. Colchicine, dinoseb, and methyl salicylate. Fundam Appl Toxicol 1988, 11(3):381-400.
• [40]Infurna R, Beyer B, Twitty L, Koehler G, Daughtrey W. Evaluation of the dermal absorption and teratogenic potential of methyl salicylate in a petroleum based grease (Abstract). Teratology. 1990;41:566.
• [41]Lamb J. Reproductive toxicology. Methyl salicylate. Environ Health Perspect. 1997;105 Suppl 1:323–4.
• [42]Morra P, Bartle WR, Walker SE, Lee SN, Bowles SK, Reeves RA: Serum concentrations of salicylic acid following topically applied salicylate derivatives. Ann Pharmacother 1996, 30(9):935-40.
• [43]Cohen M, Wolfe R, Mai T, Lewis D: A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. J Rheumatol 2003, 30(3):523-8.
• [44]Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC: Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002, 162(18):2113-23.
• [45]Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al.: Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001, 357(9252):251-6.
• [46]Nolen RS. Facing crackdown, dietary supplement companies promise changes. J Am Vet Med Assoc. 2002;221(4):479. –81, 83.
• [47]Sivojelezova A, Koren G, Einarson A: Glucosamine use in pregnancy: an evaluation of pregnancy outcome. J Womens Health (Larchmt) 2007, 16(3):345-8.
• [48]Distler J, Anguelouch A: Evidence-based practice: review of clinical evidence on the efficacy of glucosamine and chondroitin in the treatment of osteoarthritis. J Am Acad Nurse Pract 2006, 18(10):487-93.
• [49]Das A, Hammad TA: Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage 2000, 8(5):343-50.
• [50]Deal CL, Moskowitz RW: Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate, and collagen hydrolysate. Rheum Dis Clin North Am 1999, 25(2):379-95.
• [51]Bruyere O, Reginster JY: Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging 2007, 24(7):573-80.
• [52]Kamei T: Teratogenic effect of excessive chondroitin sulfate in the DON strain of mice. Med Biol 1995, 60:126-9.
• [53]Dreisinger N, Zane D, Etwaru K: A poisoning of topical importance. Pediatr Emerg Care 2006, 22(12):827-9.
• [54]Darben T, Cominos B, Lee CT: Topical eucalyptus oil poisoning. Australas J Dermatol 1998, 39(4):265-7.
• [55]Kehrl W, Sonnemann U, Dethlefsen U: Therapy for acute nonpurulent rhinosinusitis with cineole: results of a double-blind, randomized, placebo-controlled trial. Laryngoscope 2004, 114(4):738-42.
• [56]Pages N, Fournier G, Lee-Luyer F, Marques MC: Eucalyptus globus in mice. Plan Med Phyto 1990, 24:21-6.
• [57]Takahashi T, Yokoo Y, Inoue T, Ishii A: Toxicological studies on procyanidin B-2 for external application as a hair growing agent. Food Chem Toxicol 1999, 37(5):545-52.
• [58]Yamakoshi J, Saito M, Kataoka S, Kikuchi M: Safety evaluation of proanthocyanidin-rich extract from grape seeds. Food Chem Toxicol 2002, 40(5):599-607.
• [59]Ray S, Bagchi D, Lim PM, Bagchi M, Gross SM, Kothari SC, et al.: Acute and long-term safety evaluation of a novel IH636 grape seed proanthocyanidin extract. Res Commun Mol Pathol Pharmacol 2001, 109(3–4):165-97.
• [60]Erexson GL: Lack of in vivo clastogenic activity of grape seed and grape skin extracts in a mouse micronucleus assay. Food Chem Toxicol 2003, 41(3):347-50.
• [61]Thiele JJ, Ekanayake-Mudiyanselage S: Vitamin E in human skin: organ-specific physiology and considerations for its use in dermatology. Mol Aspects Med 2007, 28(5–6):646-67.
• [62]Salles AMR, Galvao TF, Silva MT, Motta LCD, Pereira MG: Antioxidants for preventing preeclampsia: a systematic review. ScientificWorldJournal 2012, 20:10-2.
• [63]Chappell LC, Seed PT, Briley AL, Kelly FJ, Lee R, Hunt BJ, et al.: Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet 1999, 354(9181):810-6.
• [64]Beazley D, Ahokas R, Livingston J, Griggs M, Sibai BM: Vitamin C and E supplementation in women at high risk for preeclampsia: a double-blind, placebo-controlled trial. Am J Obstet Gynecol 2005, 192(2):520-1.
• [65]Gulmezoglu AM, Hofmeyr GJ, Oosthuisen MM: Antioxidants in the treatment of severe pre-eclampsia: an explanatory randomised controlled trial. BJOG 1997, 104(6):689-96.
• [66]Boskovic R, Gargaun L, Oren D, Djulus J, Koren G: Pregnancy outcome following high doses of Vitamin E supplementation. Reprod Toxicol 2005, 20(1):85-8.
• [67]Siman CM, Eriksson UJ: Vitamin E decreases the occurrence of malformations in the offspring of diabetic rats. Diabetes 1997, 46(6):1054-61.
• [68]Al Deeb S, Al Moutaery K, Arshaduddin M, Tariq M: Vitamin E decreases valproic acid induced neural tube defects in mice. Neurosci Lett 2000, 292(3):179-82.
• [69]Hassoun EA, Walter AC, Alsharif NZ, Stohs SJ: Modulation of TCDD-induced fetotoxicity and oxidative stress in embryonic and placental tissues of C57BL/6 J mice by vitamin E succinate and ellagic acid. Toxicology 1997, 124(1):27-37.
• [70]Kappus H, Diplock AT: Tolerance and safety of vitamin E: a toxicological position report. Free Radic Biol Med 1992, 13(1):55-74.
• [71]Wentzel P, Eriksson UJ: Ethanol-induced fetal dysmorphogenesis in the mouse is diminished by high antioxidative capacity of the mother. Toxicol Sci 2006, 92(2):416-22.
• [72]Andersen A: Final report on the safety assessment of sodium p-chloro-m-cresol, p-chloro-m-cresol, chlorothymol, mixed cresols, m-cresol, o-cresol, p-cresol, isopropyl cresols, thymol, o-cymen-5-ol, and carvacrol. Int J Toxicol 2006, 25(Suppl 1):29-127.
• [73]Keemer EB: Looking back at Luenbach: 296 non-hospital abortions. J Natl Med Assoc 1970, 62(4):291-3.
• [74]Sood SV: Termination of pregnancy by the intrauterine insertion of Utus paste. BMJ 1971, 2(5757):315-7.
• [75]Walker AH: Termination of pregnancy using utus paste. J R Soc Med 1969, 62(8):832.
• [76]Thomas TA, Galizia EJ, Wensley RT: Termination of pregnancy with Utus paste: report of a fatal case. BMJ 1975, 1(5954):375-6.
• [77]Taiyeb-Ali TB, Zainuddin SL, Swaminathan D, Yaacob H: Efficacy of ‘Gamadent’ toothpaste on the healing of gingival tissues: a preliminary report. J Oral Sci 2003, 45(3):153-9.
• [78]Tian F, Zhu CH, Zhang XW, Xie X, Xin XL, Yi YH, et al.: Philinopside E, a new sulfated saponin from sea cucumber, blocks the interaction between kinase insert domain-containing receptor (KDR) and alphavbeta3 integrin via binding to the extracellular domain of KDR. Mol Pharmacol 2007, 72(3):545-52.
• [79]Tong Y, Zhang X, Tian F, Yi Y, Xu Q, Li L, et al.: Philinopside A, a novel marine-derived compound possessing dual anti-angiogenic and anti-tumor effects. Int J Cancer 2005, 114(6):843-53.
• [80]Zhang SY, Yi YH, Tang HF: Bioactive triterpene glycosides from the sea cucumber Holothuria fuscocinerea. J Nat Prod 2006, 69(10):1492-5.
• [81]Zhang SY, Yi YH, Tang HF, Li L, Sun P, Wu J: Two new bioactive triterpene glycosides from the sea cucumber Pseudocolochirus violaceus. J Asian Nat Prod Res 2006, 8(1–2):1-8.
• [82]Morrow DM, Rapaport MJ, Strick RA: Hypersensitivity to aloe. Arch Dermatol 1980, 116(9):1064-5.
• [83]American Botanical Council. Therapeutic Guide to Herbal Medicines. 1998. http://cms.herbalgram.org. Accessed 21 Sept 2014.
• [84]Pigatto PD, Guzzi G: Aloe linked to thyroid dysfunction. Arch Med Res 2005, 36(5):608.
• [85]Bottenberg MM, Wall GC, Harvey RL, Habib S: Oral aloe vera-induced hepatitis. Ann Pharmacother 2007, 41(10):1740-3.
• [86]Kanat O, Ozet A, Ataergin S: Aloe vera-induced acute toxic hepatitis in a healthy young man. Eur J Inter Med 2006, 17(8):589.
• [87]Suzuki I, Saito H, Inoue S, Migita S, Takahashi T: Purification and characterization of two lectins from Aloe arborescens Mill. J Biochem 1979, 85(1):163-71.
• [88]Nath D, Sethi N, Singh RK, Jain AK: Commonly used Indian abortifacient plants with special reference to their teratologic effects in rats. J Ethnopharmacol 1992, 36(2):147-54.
• [89]Parys BT: Chemical burns resulting from contact with peppermint oil mar: a case report. Burns Incl Therm Inj 1983, 9(5):374-5.
• [90]Kligler B, Chaudhary S: Peppermint oil. Am Fam Physician 2007, 75(7):1027-30.
• [91]Rees WD, Evans BK, Rhodes J: Treating irritable bowel syndrome with peppermint oil. BMJ 1979, 2(6194):835-6.
• [92]Kulkarni R, Patki P, Jog V, Gandage S, Patwardhan B: Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebo-controlled, cross-over study. J Ethnopharmacol 1991, 33(1):91-5.
• [93]Kulkarni R, Patki P, Jog V, Patwardban B: Efficacy of an Ayurvedic formulation in rheumatoid arthritis: a double-blind, placebo-controlled, cross-over study. Indian J Pharmacol 1992, 24(2):98.
• [94]Werbach MR, Murray MT: Botanical influences on illness: a sourcebook of clinical research. Third Line Press Inc, Tarzana, CA; 1994.
• [95]Gupta I, Gupta V, Parihar A, Gupta S, Ludtke R, Safayhi H, et al.: Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res 1998, 3(11):511-4.
• [96]Gupta I, Parihar A, Malhotra P, Singh GB, Ludtke R, Safayhi H, et al.: Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 1997, 2(1):37-43.
• [97]Singh GB, Bani S, Singh S: Toxicity and safety evaluation of boswellic acids. Phytomedicine 1996, 3(1):87-90.
• [98]Facts and Comparisons(R). Wolters Kluwer Health Inc, St. Louis, MO; 1996.
• [99]Claris Lifesciences Limited. Product-Information: Magnesium chloride hexahydrate IV solution. 2003. http://www.dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=50173. Accessed 21 Sep 2014.
• [100]Briggs GG, Freeman RK, Yaffe SJMD: Drugs in pregnancy and lactation. Lippincott Williams & Wilkins, Baltimore, MD; 1998.